# Dizzy on a GLP-1? The Blood-Pressure Question the Labels Skip

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-09-11 | Updated: 2026-10-31

Canonical page: https://glpwatchdog.org/research/glp1-dizziness-and-blood-pressure-pills

> Dizziness affects 4% to 8% of people on the weight-loss doses. The labels tell prescribers to lower insulin or sulfonylurea doses, and say nothing about blood-pressure pills, though low blood pressure is more common in people taking them.

## Key points

- Label dizziness rates: Wegovy 8% vs 4%, Zepbound 4-5% vs 2%, Saxenda 6.9% vs 5.0%, Foundayo 4% vs 3%.
- Low blood pressure: Wegovy 1.3% vs 0.4% (fainting 0.8% vs 0.2%); Zepbound 1.6% vs 0.1%, higher in people on blood-pressure medicines (2.2% vs 1.2%).
- The labels advise lowering insulin or sulfonylurea doses for low blood sugar; none mentions adjusting blood-pressure medication.
- In the STEP trials, 17.7% of people on blood-pressure drugs stopped all of them on semaglutide vs 9.0% on placebo; the authors note there are no guidelines for it.

Dizziness is a listed side effect of most GLP-1 drugs, and three causes are worth ruling out: blood pressure falling, blood sugar falling, or the rough first weeks of a dose increase. The labels handle two of those differently. They tell prescribers to consider lowering insulin or sulfonylurea doses. They say nothing of the kind about blood-pressure pills, even though their own figures show low blood pressure is more common in the people taking them.

> **About this article.** Written from the current FDA labels on DailyMed and the trials behind them. Nothing here is a reason to stop or change a medicine; it is a reason to ask for a review. Anything touching a dose is a question for the person who prescribes for you.

## How often it happens, by drug

Each label reports dizziness from its own placebo-controlled trials, so read each row against its own placebo column rather than comparing the drugs.[2][1][4][3]

*Source: each drug's current prescribing information on DailyMed. The Wegovy 7.2 mg figure includes dizziness on standing. The Ozempic and Mounjaro labels give no dizziness percentage.*

| Drug (label) | Dizziness on the drug | On placebo |
| --- | --- | --- |
| Wegovy, semaglutide 2.4 mg | 8% | 4% |
| Wegovy 7.2 mg trials (2.4 mg arm alongside) | 6% (5% on 2.4 mg) | 1% |
| Zepbound, tirzepatide 5 / 10 / 15 mg | 4% / 5% / 4% | 2% |
| Saxenda, liraglutide 3 mg | 6.9% | 5.0% |
| Foundayo, orforglipron | 4% | 3% |

Dizziness barely moves with the tirzepatide dose. The Ozempic label mentions it only in a line of other reactions above 0.4%, while Mounjaro’s trial table, which starts at 5%, does not list it at all.[5][6] Saxenda’s label adds the most useful timing detail: dizziness was reported mainly within the first 12 weeks, and often alongside nausea, vomiting or diarrhea.[4] Spinning vertigo and ringing ears are a separate question, covered in [GLP-1 tinnitus and hearing](https://glpwatchdog.org/research/glp1-tinnitus-and-hearing).

## Where it comes from

### Blood pressure falling

These drugs [lower blood pressure](https://glpwatchdog.org/research/glp1-and-blood-pressure),[7] and sometimes further than intended. On Wegovy, reactions related to low blood pressure were reported in 1.3% of adults against 0.4% on placebo, and fainting in 0.8% against 0.2%; the label ties some of them to stomach side effects and fluid loss,[1] which is one reason to eat and drink well before [donating blood on a GLP-1](https://glpwatchdog.org/research/glp1-and-blood-donation). On Zepbound, low blood pressure occurred in 1.6% against 0.1%, and the label says it also occurred alongside stomach side effects and dehydration.[2]

The largest look at the tirzepatide trial data found dizziness was the most common blood-pressure-related side effect: 4.6% on tirzepatide against 2.3% on placebo. Fainting was not more common (0.5% against 0.8%). Blood pressure fell fastest over the first 24 weeks, which is the period of dose increases, and then leveled off.[7] A 2026 analysis of 32 randomized trials found tirzepatide raised the risk of low-blood-pressure events (relative risk 2.45), while the increase with semaglutide was not statistically significant.[9] What the blood-pressure fall means for heart health is covered in [what else GLP-1 drugs change](https://glpwatchdog.org/research/what-else-glp1-drugs-change).

### Blood sugar falling

Every Medication Guide includes “dizziness or light-headedness” in its list of low-blood-sugar warning signs, and names insulin or a sulfonylurea as what raises the risk.[2] On the Zepbound label, low blood sugar was reported by 10.3% of people also taking a sulfonylurea against 2.1% of those who were not.[2] Who is at risk is worked through in [GLP-1 drugs and low blood sugar](https://glpwatchdog.org/research/glp1-low-blood-sugar-risk).

## The instruction the labels leave out

For blood sugar, the labels say what to do. Zepbound’s says cutting the insulin or sulfonylurea dose can bring the low-blood-sugar risk down.[2] For blood pressure there is no equivalent. The only mention of blood-pressure medicines in any of these labels is a finding, not an instruction: low blood pressure was more common in people also on one. On Zepbound that was 2.2% against 1.2%; on Foundayo, 4% against 1%; Wegovy says it was more frequent without giving figures.[2][3][1]

The trials show the adjustment happening anyway. Across [the STEP semaglutide trials](https://glpwatchdog.org/research/lists/top-semaglutide-weight-loss-studies), 17.7% of people on blood-pressure medicines stopped all of them on semaglutide, against 9.0% on placebo, and 16.5% reduced them against 4.8%. The authors noted that doctors are not used to cutting these drugs back, “especially as there are no guidelines to provide direction in the absence of hypotension or other adverse effect.”[8] For tirzepatide there is no comparable record: the main trial let investigators adjust blood-pressure drugs but “did not collect robust information on medication changes.”[7]

> If you take a blood-pressure medicine and start feeling dizzy or light-headed, particularly when you stand up and particularly in the weeks after a dose increase, that is a reason to ask the prescriber for a medication review. It is not a reason to stop a pill on your own; blood-pressure medicines are prescribed for reasons that do not go away with a number on a cuff.

## When dizziness is urgent

- **Fainting or feeling dizzy together with a swollen face or throat, difficulty breathing, or a very rapid heartbeat.** The Zepbound Medication Guide lists these as signs of a serious allergic reaction: stop the drug and get medical help right away.[2]
- **Dizziness with sweating, shakiness or confusion while taking insulin or a sulfonylurea.** These are low-blood-sugar signs, and the Medication Guides tie that risk to those medicines.[2]
- **Vomiting or diarrhea that will not stop.** The labels warn that the fluid loss can injure the kidneys; see [GLP-1 diarrhea](https://glpwatchdog.org/research/glp1-diarrhea-what-helps) and [GLP-1 drugs and your kidneys](https://glpwatchdog.org/research/glp1-and-your-kidneys).
- **A racing heartbeat at rest.** Wegovy’s label asks patients to tell their prescriber about palpitations or a racing heart while resting.[1] [Why a GLP-1 raises your heart rate](https://glpwatchdog.org/research/glp1-heart-rate-and-palpitations) covers which labels warn about it and which do not.

## Frequently asked questions

### Can Ozempic, Wegovy, Mounjaro or Zepbound make you dizzy?

Yes for most of them. In the trials behind each label, dizziness was reported by 8% on Wegovy against 4% on placebo, 4% to 5% on Zepbound against 2%, 6.9% on Saxenda against 5.0%, and 4% on Foundayo against 3%. The Ozempic label mentions it only among other reactions above 0.4%, and Mounjaro's trial table does not list it.

### Why do GLP-1 drugs make you dizzy?

The labels point to three routes: blood pressure falling, low blood sugar in people who also use insulin or a sulfonylurea, and the early weeks of treatment, when dizziness is often reported alongside nausea, vomiting or diarrhea. In the tirzepatide trial, blood pressure fell fastest in the first 24 weeks, during the dose increases.

### Should I lower my blood pressure medication on a GLP-1?

Not on your own. No FDA label for these drugs tells prescribers to adjust blood-pressure medicines, but the trials show it happens: 17.7% of STEP participants on those medicines stopped all of them on semaglutide, against 9.0% on placebo, and the authors note there are no guidelines for doing it. If you feel dizzy or light-headed, ask your prescriber for a medication review.

### Does tirzepatide cause low blood pressure more than semaglutide?

One 2026 analysis of 32 randomized trials found tirzepatide raised the risk of low-blood-pressure events, with a relative risk of 2.45, while semaglutide's increase was not statistically significant. On the Zepbound label, low blood pressure occurred in 1.6% against 0.1% on placebo, and more often in people also taking blood-pressure medicines.

### When is dizziness on a GLP-1 an emergency?

When it comes with a swollen face or throat, difficulty breathing or a very rapid heartbeat, which the labels list as signs of a serious allergic reaction; when it comes with sweating, shakiness or confusion while you take insulin or a sulfonylurea; or when vomiting or diarrhea will not stop. Get help right away in the first case and contact your prescriber in the others.

## References

1. Novo Nordisk WEGOVY (semaglutide) injection and tablets — prescribing information and Medication Guide (sections 5.9, 6.1). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. Eli Lilly and Company ZEPBOUND (tirzepatide) injection — prescribing information and Medication Guide (sections 5.7, 6.1). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
3. Eli Lilly and Company FOUNDAYO (orforglipron) tablets — prescribing information (section 6.1). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
4. Novo Nordisk SAXENDA (liraglutide) injection — prescribing information (section 6.1). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
5. Novo Nordisk OZEMPIC (semaglutide) injection — prescribing information (section 6.1). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
6. Eli Lilly and Company MOUNJARO (tirzepatide) injection — prescribing information (section 6.1, Table 1). DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
7. Krumholz HM, de Lemos JA, Sattar N, et al. Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial. Heart. 2024. PMID: 39084707. https://pubmed.ncbi.nlm.nih.gov/39084707/
8. Tchang BG, Knight MG, Adelborg K, et al. Effect of semaglutide 2.4 mg on use of antihypertensive and lipid-lowering treatment in five randomized controlled STEP trials. Obesity. 2025. PMID: 39756397. https://pubmed.ncbi.nlm.nih.gov/39756397/
9. Chen QX, Zhou XY, Wu Q, et al. Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis. Endocrine. 2026. PMID: 42603240. https://pubmed.ncbi.nlm.nih.gov/42603240/

---

Cite as: GLP Watchdog, Ruth Calder, "Dizzy on a GLP-1? The Blood-Pressure Question the Labels Skip", published 2026-09-11, updated 2026-10-31. https://glpwatchdog.org/research/glp1-dizziness-and-blood-pressure-pills

Canonical HTML page: https://glpwatchdog.org/research/glp1-dizziness-and-blood-pressure-pills

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.